<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127837</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00009140</org_study_id>
    <secondary_id>5R42MH123215-02</secondary_id>
    <nct_id>NCT05127837</nct_id>
  </id_info>
  <brief_title>CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Techniques</brief_title>
  <acronym>CBTpro</acronym>
  <official_title>Development of an Artificial Intelligence- Informed Digital Tool to Help Clinicians Practice Cognitive Behavioral Therapy for Psychosis (CBTp)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this grant is to develop and evaluate a spoken language technology&#xD;
      tool -- CBTpro -- to support high-quality skills training in CBT for psychosis (CBTp). CBTpro&#xD;
      will provide a rapid means of scaling and sustaining high-quality CBTp in routine care&#xD;
      settings across the US.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This fast-track Small Business Technology Transfer (STTR) grant is a partnership between the&#xD;
      University of Washington and private company LYSSN that includes building a prototype,&#xD;
      CBTpro, which is a training platform designed for clinicians to use to learn CBT for&#xD;
      psychosis. The tool uses speech processing to provide automated speech-to-text and machine&#xD;
      learning models to score trainee's responses to patient scenarios online.&#xD;
&#xD;
      Once technical reliability of the tool is achieved through iterative modifications based on&#xD;
      usability data and field trial, we will conduct an RCT of CBTpro training vs. training as&#xD;
      usual with N=100 providers / N=300 clients and assess it's impact on clinician skills and&#xD;
      client clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2022</start_date>
  <completion_date type="Anticipated">January 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>0,3,6 months</time_frame>
    <description>The PANSS is a semi-structured interview assessing 20 symptoms (7 positive, 7 negative, 16 general psychopathology), each rated on a 7-point Likert scale, with higher ratings corresponding to more severe symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Recovery Assessment Scale (RAS)</measure>
    <time_frame>0,3,6 months</time_frame>
    <description>The RAS is a 41 item scale rated on a 5-point agreement Likert Scale (5=strongly agree) assessing self-esteem, empowerment, social support and quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WHO Disability Assessment Schedule 2.0 (WHODAS)</measure>
    <time_frame>0,3,6 months</time_frame>
    <description>The WHODAS is a 36 item scale that loads into six domains of functioning: cognition, mobility, self-care, getting along, life activities and community participation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Psychosis</condition>
  <condition>Schizophrenia</condition>
  <condition>Schizo Affective Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>TAU</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>CBTp distance learning course.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBTpro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to TAU, clinicians and clients receive the CBTpro training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBTpro</intervention_name>
    <description>CBTpro is a novel spoken language technology tool to support high-quality skills training in CBT for psychosis.</description>
    <arm_group_label>CBTpro</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Provider Inclusion Criteria:&#xD;
&#xD;
          -  Frontline clinical staff who provide direct clinical services to adult outpatients at&#xD;
             designated study sites&#xD;
&#xD;
          -  Providers must carry a caseload that includes adults with primary psychotic disorders&#xD;
             and / or major mood disorders with psychotic features&#xD;
&#xD;
        Provider Exclusion Criteria:&#xD;
&#xD;
          -  Providers who participated in previous activities for this grant&#xD;
&#xD;
          -  Providers who have been previously trained in CBTp&#xD;
&#xD;
        Client Inclusion Criteria:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
          -  English-speaking and can read English at a 4th grade level or higher&#xD;
&#xD;
          -  Chart diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder,&#xD;
             bipolar or depressive disorder with psychotic features, brief psychotic disorder,&#xD;
             other specified psychotic disorder, unspecified schizophrenia spectrum and other&#xD;
             psychotic disorder.&#xD;
&#xD;
          -  Working with a provider who is enrolled in the study&#xD;
&#xD;
          -  Can provide consent&#xD;
&#xD;
        Client Exclusion Criteria:&#xD;
&#xD;
          -  Psychosis secondary to substance intoxication, withdrawal or medical condition&#xD;
&#xD;
          -  Unwilling to commit to weekly or biweekly clinic-based appointments&#xD;
&#xD;
          -  Unwilling to consent to have clinic sessions recorded&#xD;
&#xD;
          -  Plan to move or discontinue services at a participating clinic over the 6-month study&#xD;
             period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Kopelovich, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel M Brian, MPH</last_name>
    <phone>206-221-1218</phone>
    <email>rbrian@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Valley Cities Behavioral Health Care</name>
      <address>
        <city>Auburn</city>
        <state>Washington</state>
        <zip>98002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Healthcare</name>
      <address>
        <city>Ellensburg</city>
        <state>Washington</state>
        <zip>98926</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Cities Behavioral Health Care</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Healthcare</name>
      <address>
        <city>Goldendale</city>
        <state>Washington</state>
        <zip>98620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Cities Behavioral Health Care</name>
      <address>
        <city>Kent</city>
        <state>Washington</state>
        <zip>98032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Cities Behavioral Health Care</name>
      <address>
        <city>Midway</city>
        <state>Washington</state>
        <zip>98198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Cities Behavioral Health Care</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Healthcare</name>
      <address>
        <city>Sunnyside</city>
        <state>Washington</state>
        <zip>98944</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Healthcare</name>
      <address>
        <city>Walla Walla</city>
        <state>Washington</state>
        <zip>99362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Healthcare</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Sarah Kopelovich</investigator_full_name>
    <investigator_title>Assistant Professor, School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Clinician Training</keyword>
  <keyword>AI (artificial Intelligence)</keyword>
  <keyword>Machine learning</keyword>
  <keyword>NLP (natural language processing)</keyword>
  <keyword>Cognitive Behavioral Therapy (CBT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Research subject's de-identified data will be shared through the National Institute of Mental Health Data Archive (NDA).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

